id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0066-0007,FDA,FDA-2003-E-0066,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Grace J. Fishel,Rule,Certificate Extending Patent Term,2006-09-15T04:00:00Z,2006,9,,,2025-10-30T22:39:23Z,,0,0,0900006480481c09
FDA-2003-E-0066-0006,FDA,FDA-2003-E-0066,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2005-04-19T04:00:00Z,2005,4,,,2025-10-30T22:37:39Z,,0,0,0900006480481c06
FDA-2003-E-0066-0005,FDA,FDA-2003-E-0066,Determination of Regulatory Review Period for Purposes of Patent Extension; NEUTERSOL,Notice,General Notice,2004-07-09T04:00:00Z,2004,7,2004-07-07T04:00:00Z,,2025-10-30T22:35:22Z,04-15301,0,0,0900006480481c04
FDA-2003-E-0066-0004,FDA,FDA-2003-E-0066,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-06-28T04:00:00Z,2004,6,,,2025-10-30T22:30:13Z,,0,0,0900006480481c02
FDA-2003-E-0066-0003,FDA,FDA-2003-E-0066,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2004-01-16T05:00:00Z,2004,1,,,2025-10-30T22:27:47Z,,0,0,0900006480481bff
FDA-2003-E-0066-0002,FDA,FDA-2003-E-0066,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-24T05:00:00Z,2003,11,,,2025-10-30T22:23:08Z,,0,0,0900006480481bfd
FDA-2003-E-0066-0001,FDA,FDA-2003-E-0066,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-09-26T04:00:00Z,2003,9,,,2025-10-30T22:13:55Z,,0,0,0900006480481b95